Clinuvel Pharmaceuticals (ASX:CUV) said it is in talks with the European Medicines Agency (EMA) to increase the recommended maximum dose of its drug Scenesse for adult patients with erythropoietic protoporphyria (EPP), according to a Wednesday filing with the Australian bourse.
EPP is an inherited condition characterized by extreme photosensitivity and could lead to liver disease.
The EMA's Pharmacovigilance Risk Assessment Committee will decide whether to maintain the existing drug label or expand it to up to six times per year, the filing said.
The outcome is expected by the first quarter of 2025, according to the filing.
Clinuvel Pharmaceuticals' shares were down more than 2% in recent Wednesday trade.
Price (AUD): $13.30, Change: $-0.32, Percent Change: -2.39%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.